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Abstract: Neoadjuvant chemoradiation (nCRT) is an established procedure in stage union
internationale contre le cancer (UICC) II/III rectal carcinomas. Around 53% of the tumours
present with good tumor regression after nCRT, and 8%–15% are complete responders. Reliable
selection markers would allow the identification of poor or non-responders prior to therapy. Tumor
biopsies were harvested from 20 patients with rectal carcinomas, and stored in liquid nitrogen
prior to therapy after obtaining patients’ informed consent (Erlangen-No.3784). Patients received
standardized nCRT with 5-Fluoruracil (nCRT I) or 5-Fluoruracil ˘ Oxaliplatin (nCRT II) according
to the CAO/ARO/AIO-04 protocol. After surgery, regression grading (Dworak) of the tumors was
performed during histopathological examination of the specimens. Tumors were classified as poor
(Dworak 1 + 2) or good (Dworak 3 + 4) responders. Laser capture microdissection (LCM) for tumor
enrichment was performed on preoperative biopsies. Differences in expressed proteins between
poor and good responders to nCRT I and II were identified by proteomic analysis (Isotope Coded
Protein Label, ICPL™) and selected markers were validated by immunohistochemistry. Tumors
of 10 patients were classified as histopathologically poor (Dworak 1 or 2) and the other 10 tumor
samples as histopathologically good (Dworak 3 or 4) responders to nCRT after surgery. Sufficient
material in good quality was harvested for ICPL analysis by LCM from all biopsies. We identified
140 differentially regulated proteins regarding the selection criteria and the response to nCRT.
Fourteen of these proteins were synchronously up-regulated at least 1.5-fold after nCRT I or nCRT II
(e.g., FLNB, TKT, PKM2, SERINB1, IGHG2). Thirty-five proteins showed a complete reciprocal
regulation (up or down) after nCRT I or nCRT II and the rest was regulated either according to nCRT
I or II. The protein expression of regulated proteins such as PLEC1, TKT, HADHA and TAGLN was
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validated successfully by immunohistochemistry. ICPL is a valid method to identify differentially
expressed proteins in rectal carcinoma tissue between poor vs. good responders to nCRT. The
identified protein markers may act as selection criteria for nCRT in the future, but our preliminary
findings must be reproduced and validated in a prospective cohort.
Keywords: rectal cancer; chemoradiation; proteomic; ICPL
1. Introduction
Neoadjuvant chemoradiation (nCRT) is an established procedure for locally advanced rectal
carcinomas stage union internationale contre le cancer (UICC) II and lymph node positive rectal
carcinomas stage UICC III [1–5]. Local tumor control is improved by nCRT. The percentage of
sphincter preservation rate is increased and local recurrence rates after complete surgical removal of
the tumor (R0) is decreased [4,6]. No improvement on overall patients’ survival is noted after nCRT [4].
The response to nCRT varies considerably with the patient cohorts. Applying the histopathological
regression grading described by Dworak, poor regression was observed in 15%, intermediate regression
in 70% and complete regression in 15% of the carcinomas [7]. The regression rate seems to improve
prognosis significantly and there may be a correlation between tumor response, distant metastasis
and patients’ survival [8]. However, in 6% of complete tumor response to nCRT (ypT0) lymph node
metastases can be detected in the resected specimens. Lymph node metastases are considered as crucial
prognostic indicators [8].
Neoadjuvant therapy comes with costs, not only is it associated with toxic side effects but it also
represents an economic burden. Because the therapeutic effect of nCRT is variable and around 15% of
the treated patients do not experience a therapeutic benefit at all, a case selection prior to therapy is
desirable [9]. But currently no predictive indicators for nCRT response exist for routine clinical use.
Today selection for nCRT is based on imaging techniques. These imaging techniques have limitations
in detecting tumor-affected lymph nodes. Molecular markers of the tumor would be ideal to select
patients, because they can be analysed prior to therapy in endoscopically harvested tissues. As of
today no such markers exist.
To identify molecular markers predictive for nCRT therapy response, we analyzed the proteome of
laser captured micro dissected rectal carcinoma biopsies prior to nCRT with isotope coded protein label
(ICPL), a recent quantitative technique for protein analysis [10,11]. These results were postoperatively
correlated with histopathological tumor response grade (Dworak) of the resected specimens.
2. Results
2.1. Tumor Samples and Laser Capture Microdissection
We harvested two tumor biopsies from rectal carcinomas from each patient prior to nCRT. One
was harvested in liquid nitrogen and stored at´80 ˝C for proteome analysis, the second one underwent
formalin fixation and paraffin embedding procedure (FFPE) fixation for immunohistochemistry. No
complications occurred during biopsy sampling. Fresh frozen samples were cut in 8–10 µm slices and
prepared for Laser capture microdissection (LCM) as described. A total of 100 mm2 pure tumor tissue
was collected by LCM. There was sufficient tumor material within a 5 mm tumor biopsy to harvest
this amount of carcinoma. From 100 mm2 of tumor tissue an amount of 20 µg total protein could be
isolated for ICPL.
2.2. Proteome Analysis by Isotope Coded Protein Label (ICPL)
The proteome analysis of the 2 ˆ 24 OFFGEL-fraction and the non-fractionated samples
(50 samples in total) was performed via ICPL-ESIQuant Software. Proteins were referred as quantified
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and identified with at least two multiplets per protein and a unique peptide per protein. A protein
was identified as a single protein species in neighbouring OFFGEL-fractions, whereas, a protein was
identified as a separate protein species or isoform in several non side-by-side OFFGEL-fractions. In
total 3222 protein species were detected in all 24 fractions of the first OFFGEL-analysis (645 unique
protein species). However, because many of the proteins have been found in several fractions, this
number was reduced to 131. In the second technical replicate, 3734 protein species were detected
in total in all 24 fractions of the OFFGEL-analysis (734 unique protein species). Likewise proteins
appearing in several fractions were removed, with 146 proteins left over. Eight-two proteins were
identical in both technical replicates. In the first analysis of the not-fractionated samples, from in
total 291 detected protein species, 62 unique proteins were identified. The second analysis of the
non-fractionated samples could not be included in the evaluation, because that generated by the
LC-MS/MS spectra did not permit reliable statements. A repeat of the experiment could not be
performed due to insufficient sample amount. Forty-two of the identified proteins were found in all
analyses (fractionated and non-fractionated). The identified proteins were classified as differentially
expressed with a regulation value of 1.5 ě 1 ě 0.66, with at least two quadruplets per protein and
a unique peptide per protein (CV ď 30%). The analysis for nCRT I and nCRT II was carried out
separately because of the different chemotherapy regimens added to radiation therapy. Thus, in the
data set of nCRT I, 201 proteins (non-redundant) were identified in 2 ˆ 24 OFFGEL fractions and in
the non-fractioned sample and the corresponding protein IDs are allocated from the IPI database; of
these, 140 proteins could meet the described regulation value. Out of these 140 differentially regulated
proteins, 79 proteins are downregulated in the proteome of poor/moderate responses of nCRT I and
61 proteins were upregulated. In the data set of nCRT II, and 201 proteins (non-redundant) were
identified in 2ˆ 24 OFFGEL fractions and in the non-fractioned sample, and the corresponding protein
IDs are allocated from the IPI database. Of these, 114 proteins met the described regulation values.
Out of these 114 differentially regulated proteins, 91 proteins are downregulated in the proteome of
poor/moderate responses of nCRT 1 and 23 proteins were upregulated.
Fourteen of these proteins showed a synchronous regulation after nCRT I and 2: A high
expression of FLNB Isoform 1 of Filamin-B, Transketolase, PKM2 Isoform M2 of Pyruvate kinase
isozymes M1/M2 and SERPINB1 Leukocyte elastase inhibitor and a low expression of IGHG2,
Putative uncharacterized protein DKFZp686C15213 was particularly predictive for nCRT without any
preference to the added chemotherapy throughout the applied RCT regiments. Thirty-five proteins
were completely reciprocally regulated in response to nCRT I vs. nCRT II. Transgelin, LOC440786 Ig
kappa chain V–II region TEW and kappa light chain variable region (Fragment) were highly expressed
in good responders to nCRT II and expressed at very low levels in good responders to nCRT I. But
heterogeneous nuclear ribonucleoprotein F, Adenine phosphoribosyltransferase (APRT) or Tubulin
α-1C chain (TUBA1C) were highly expressed in response to nCRT I and expressed at very low levels
in response to nCRT II. Eighty-nine proteins were regulated either in response to nCRT I or II. Of
these proteins thirty eight were upregulated and 20 down-regulated in good response to nCRT I.
Peroxiredoxin-4 (PRDX4), Tubulin α-1A chain (TUBA1A) and Fatty acid-binding protein, epidermal
(FABP5; FABP5L7) were highly expressed and Isoform 1 of Fibrinogen α chain precursor (FGA),
Isoform 1 of Caldesmon (CALD1) or Isoform Gamma-A of Fibrinogen gamma chain precursor (FGG)
were very low expressed in response to nCRT I. Twenty-one proteins were up and 10 proteins were
down regulated in response to nCRT II. Of these proteins Actin, α skeletal muscle (ACTA1), Actin,
α cardiac muscle 1 (ACTC1) and filamin A, α isoform 1 (FLNA) were extremely highly expressed
and Histone H1.5 (HIST1H1B) and 60S ribosomal protein L1i3a (RPL13A) were expressed at very low
levels in response to nCRT II. A detailed list of differentially regulated proteins is provided in Table 1.
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Table 1. Differentially regulated proteins identified by isotope coded protein label (isotope coded
protein label (ICPL)) between poor (Dworak 1 + 2) and good (Dworak 3 + 4) responders to neoadjuvant
chemoradiation (nCRT) I or II; n.r.: not regulated regarding the selection criteria (regulation value
1.5 ě 1 ě 0.66 and CV ď 30%); nCRT I: 50.4 Gy + 5-FU; nCRT II: 50.4 Gy + 5-FU/Oxaliplatin.
Accession
Number Protein Name
Protein Expression ICPL in
nCRT I (Dworak
1 + 2/Dworak 3 + 4)
Protein Expression ICPL in
nCRT II (Dworak
1+2/Dworak 3 + 4)
Synchronously regulated proteins in nCRT I and II
IPI00006663 ALDH2 Aldehyde dehydrogenase,mitochondrial precursor 0.53 0.53
IPI00010290 FABP1 FABP1 protein (Fragment) 0.54 0.33
IPI00013847 UQCRC1 Cytochrome b-c1 complexsubunit 1, mitochondrial precursor 0.63 0.52
IPI00014898 PLEC1 Isoform 1 of Plectin-1 0.48 0.43
IPI00026185 CAPZB Isoform 1 of F-actin-cappingprotein subunit beta 0.64 0.58
IPI00027444 SERPINB1 Leukocyte elastaseinhibitor 0.30 0.49
IPI00216256 WDR1 Isoform 2 of WDrepeat-containing protein 1 0.40 0.56
IPI00289334 FLNB Isoform 1 of Filamin-B 0.36 0.39
IPI00298860 LTF Growth-inhibiting protein 12 0.56 0.41
IPI00337335 MYH14 Isoform 1 of Myosin-14 0.41 0.57
IPI00426051 IGHG2, Putative uncharacterizedprotein DKFZp686C15213 2.36 2.35
IPI00479186 PKM2 Isoform M2 of Pyruvatekinase isozymes M1/M2 0.43 0.43
IPI00643920 TKT Transketolase 0.38 0.47
IPI00793199 ANXA4 annexin IV 0.41 0.58
Up regulated proteins in good responders (Dworak 3 + 4) nCRT I
IPI00000105 MVP Major vault protein 0.48 n.r.
IPI00000874 PRDX1 Peroxiredoxin-1 0.59 n.r.
IPI00004657 HLA-B major histocompatibilitycomplex, class I, B 0.45 n.r.
IPI00007750 TUBA4A Tubulin α-4A chain 0.37 n.r.
IPI00007752 TUBB2C Tubulin beta-2C chain 0.40 n.r.
IPI00007797 FABP5;FABP5L7 Fatty acid-bindingprotein, epidermal 0.31 n.r.
IPI00008274 CAP1 Adenylylcyclase-associated protein 0.55 n.r.
IPI00010133 CORO1A Coronin-1A 0.57 n.r.
IPI00010154 GDI1 Rab GDP dissociationinhibitor α 0.53 n.r.
IPI00011654 TUBB Tubulin beta chain 0.51 n.r.
IPI00011937 PRDX4 Peroxiredoxin-4 0.11 n.r.
IPI00013683 TUBB3 Tubulin beta-3 chain 0.50 n.r.
IPI00013881 HNRPH1 Heterogeneous nuclearribonucleoprotein H 0.59 n.r.
IPI00013890 SFN Isoform 1 of 14-3-3protein sigma 0.44 n.r.
IPI00024095 ANXA3 Annexin A3 0.51 n.r.
IPI00025252 PDIA3 Protein disulfide-isomeraseA3 precursor 0.49 n.r.
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Table 1. Cont.
Accession
Number Protein Name
Protein Expression ICPL in
nCRT I (Dworak
1 + 2/Dworak 3 + 4)
Protein Expression ICPL in
nCRT II (Dworak
1+2/Dworak 3 + 4)
IPI00025874
RPN1
Dolichyl-diphosphooligosaccharide–protein
glycosyltransferase 67 kDa
subunit precursor
0.50 n.r.
IPI00027463 S100A6 Protein S100-A6 0.49 n.r.
IPI00028931 DSG2 Desmoglein-2 precursor 0.49 n.r.
IPI00031461 GDI2 Rab GDP dissociationinhibitor beta 0.56 n.r.
IPI00169383 PGK1 Phosphoglycerate kinase 1 0.42 n.r.
IPI00171903
HNRPM Isoform 1 of
Heterogeneous nuclear
ribonucleoprotein M
0.65 n.r.
IPI00180675 TUBA1A Tubulin α-1A chain 0.31 n.r.
IPI00216049 HNRPK Isoform 1 of Heterogeneousnuclear ribonucleoprotein K 0.50 n.r.
IPI00218782 CAPZB Capping protein 0.64 n.r.
IPI00218852 VIL1 Villin-1 0.50 n.r.
IPI00219153 RPL22 60S ribosomal protein L22 0.53 n.r.
IPI00220644 PKM2 Isoform M1 of Pyruvatekinase isozymes M1/M2 0.53 n.r.
IPI00220739 PGRMC1 Membrane-associatedprogesterone receptor component 1 0.56 n.r.
IPI00297779 CCT2 T-complex protein 1subunit beta 0.46 n.r.
IPI00299000 PA2G4 Proliferation-associatedprotein 2G4 0.46 n.r.
IPI00401264
TXNDC4 Thioredoxin
domain-containing protein
4 precursor
0.48 n.r.
IPI00410693
SERBP1 Isoform 1 of Plasminogen
activator inhibitor 1
RNA-binding protein
0.51 n.r.
IPI00419585
PPIA;PPIAL3;LOC654188
Peptidyl-prolyl cis-trans
isomerase A
0.59 n.r.
IPI00419880 RPS3A 40S ribosomal protein S3a 0.39 n.r.
IPI00465431 LGALS3 Galectin-3 0.46 n.r.
IPI00465439 ALDOA Fructose-bisphosphatealdolase A 0.47 n.r.
IPI00472855
HLA-A HLA class I
histocompatibility antigen, A-30 α
chain precursor
0.45 n.r.
Down regulated proteins in good responders (Dworak 3 + 4) nCRT I
IPI00010790 BGN Biglycan precursor 2.46 n.r.
IPI00014516 CALD1 Isoform 1 of Caldesmon 3.16 n.r.
IPI00020986 LUM Lumican precursor 2.22 n.r.
IPI00021885 FGA Isoform 1 of Fibrinogen αchain precursor 4.12 n.r.
IPI00021891 FGG Isoform Gamma-B ofFibrinogen gamma chain precursor 3.04 n.r.
IPI00022391 APCS Serum amyloidP-component precursor 2.41 n.r.
IPI00022395 C9 Complement componentC9 precursor 1.74 n.r.
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Table 1. Cont.
Accession
Number Protein Name
Protein Expression ICPL in
nCRT I (Dworak
1 + 2/Dworak 3 + 4)
Protein Expression ICPL in
nCRT II (Dworak
1+2/Dworak 3 + 4)
IPI00022418 FN1 Isoform 1 ofFibronectin precursor 2.26 n.r.
IPI00029717 FGA Isoform 2 of Fibrinogen αchain precursor 1.90 n.r.
IPI00031008 TNC Isoform 1 of Tenascin precursor 1.89 n.r.
IPI00168728 IGHM FLJ00385 protein (Fragment) 1.82 n.r.
IPI00215983 CA1 Carbonic anhydrase 1 1.79 n.r.
IPI00216134 TPM1 tropomyosin 1 α chainisoform 7 3.04 n.r.
IPI00218695 CALD1 Isoform 3 of Caldesmon 2.55 n.r.
IPI00219713 FGG Isoform Gamma-A ofFibrinogen gamma chain precursor 3.05 n.r.
IPI00298497 FGB Fibrinogen beta chain precursor 2.64 n.r.
IPI00399007 IGHG2 Putative uncharacterizedprotein DKFZp686I04196 (Fragment) 1.83 n.r.
IPI00472961 IGKC IGKC protein 2.08 n.r.
IPI00550640 IGHG4 IGHG4 protein 2.30 n.r.
IPI00553153 ATPIF1 Putative uncharacterizedprotein DKFZp564G0422 1.86 n.r.
Up regulated proteins in good responders (Dworak 3 + 4) nCRT II
IPI00001539 ACAA2 3-ketoacyl-CoA thiolase,mitochondrial n.r. 0.48
IPI00003269
Beta-actin-like protein
2_DKFZp686D0972 hypothetical
protein LOC345651
n.r. 0.52
IPI00008603 ACTA2 Actin, aortic smooth muscle n.r. 0.58
IPI00011107 IDH2 Isocitrate dehydrogenase[NADP], mitochondrial precursor n.r. 0.23
IPI00013508 ACTN1 α-actinin-1 n.r. 0.52
IPI00019502 MYH9 Myosin-9 n.r. 0.40
IPI00021428 ACTA1 Actin, α skeletal muscle n.r. 0.19
IPI00021439 ACTB Actin, cytoplasmic 1 n.r. 0.57
IPI00021440 Actin, cytoplasmic 2 n.r. 0.45
IPI00023006 ACTC1 Actin, α cardiac muscle 1 n.r. 0.29
IPI00024145 VDAC2 Voltage-dependentanion-selective channel protein 2 n.r. 0.46
IPI00024870 MYH11 smooth muscle myosinheavy chain 11 isoform SM2A n.r. 0.50
IPI00024919
PRDX3 Thioredoxin-dependent
peroxide reductase,
mitochondrial precursor
n.r. 0.53
IPI00031522 HADHA Trifunctional enzymesubunit α, mitochondrial precursor n.r. 0.38
IPI00103467 ALDH1B1 Aldehyde dehydrogenaseX, mitochondrial precursor n.r. 0.27
IPI00216308 VDAC1 Voltage-dependentanion-selective channel prote n.r. 0.45
IPI00217975 LMNB1 Lamin-B1 n.r. 0.47
IPI00291006 MDH2 Malate dehydrogenase,mitochondrial precursor n.r. 0.46
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Accession
Number Protein Name
Protein Expression ICPL in
nCRT I (Dworak
1 + 2/Dworak 3 + 4)
Protein Expression ICPL in
nCRT II (Dworak
1+2/Dworak 3 + 4)
IPI00302592 FLNA filamin A, α isoform 1 n.r. 0.22
IPI00418169 ANXA2 annexin A2 isoform 1 n.r. 0.50
IPI00555733 Actin-like protein (Fragment) n.r. 0.61
Down regulated proteins in good responders (Dworak 3 + 4) nCRT II
IPI00002535
FKBP2 FK506-binding protein 2
precursor_Peptidyl-prolyl cis-trans
isomerase FKBP2
n.r. 1.70
IPI00014263
EIF4H;LOC653994 Isoform Long of
Eukaryotic translation initiation
factor 4H
n.r. 1.85
IPI00021841 APOA1 Apolipoprotein A-Iprecursor n.r. 1.78
IPI00032313 S100A4 Protein S100-A4 n.r. 0.23
IPI00102821 MGC29506 hypothetical proteinLOC51237 n.r. 2.58
IPI00217468 HIST1H1B Histone H1.5 n.r. 2.16
IPI00304612 RPL13A 60S ribosomal protein L13a n.r. 1.83
IPI00412714
SERBP1 Isoform 4 of Plasminogen
activator inhibitor 1 RNA-binding
protein
n.r. 1.68.
IPI00470498
SERBP1 Isoform 3 of Plasminogen
activator inhibitor 1
RNA-binding protein
n.r. 1.71
IPI00479997 STMN1 Stathmin n.r. 1.65
Reciprocal regulated proteins in nCRT I and II
IPI00000230 TPM1 tropomyosin 1 α chainisoform 2 2.58 0.47
IPI00003881 HNRPF Heterogeneous nuclearribonucleoprotein F 0.31 2.26
IPI00003949 UBE2N Ubiquitin-conjugatingenzyme E2 N 0.52 1.51
IPI00004573 PIGR Polymeric immunoglobulinreceptor precursor 0.56 1.78
IPI00008176 SHROOM4 Isoform 1 ofProtein Shroom4 2.26 0.53
IPI00022792 MFAP4 Microfibril-associatedglycoprotein 4 precursor 4.81 0.09
IPI00096066
SUCLG2 Succinyl-CoA ligase
(GDP-forming) beta-chain,
mitochondrial precursor
2.13 0.46
IPI00010779 TPM4 Isoform 1 of Tropomyosin
α-4 chain 2.44 0.30
IPI00016801 GLUD1 Glutamate dehydrogenase 1,mitochondrial precursor 1.18 0.50
IPI00018853 TPM1 Tropomyosin isoform 1.87 0.54
IPI00020501 MYH11 Myosin-11 3.09 0.43
IPI00218820 TPM2 Isoform 3 of Tropomyosinbeta chain 2.09 0.52
IPI00218693 APRT Adeninephosphoribosyltransferase 0.53 2.02
IPI00219757 GSTP1 Glutathione S-transferase P 043 1.85
IPI00025512 HSPB1 Heat shock protein beta-1 1.55 0.41
IPI00027350 PRDX2 Peroxiredoxin-2 2.18 0.49
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Table 1. Cont.
Accession
Number Protein Name
Protein Expression ICPL in
nCRT I (Dworak
1 + 2/Dworak 3 + 4)
Protein Expression ICPL in
nCRT II (Dworak
1+2/Dworak 3 + 4)
IPI00183968 TPM3 tropomyosin 3 isoform 1 2.00 0.30
IPI00216135 TPM1 Isoform 3 of Tropomyosin
α-1 chain 2.28 0.51
IPI00216138 TAGLN Transgelin 4.03 0.28
IPI00218319 TPM3 Isoform 2 of Tropomyosin
α-3 chain 2.44 0.56
IPI00218343 TUBA1C Tubulin α-1C chain 0.36 2.10
IPI00220362 HSPE1 10 kDa heat shock protein,mitochondrial 1.78 0.49
IPI00220709 TPM2 Isoform 2 of Tropomyosinbeta chain 2.52 0.51
IPI00299547
LCN2 Neutrophil
gelatinase-associated
lipocalin precursor
0.46 1.90
IPI00333771 CALD1 Isoform 5 of Caldesmon 3.16 0.55
IPI00335168 MYL6 Isoform Non-muscle ofMyosin light polypeptide 6 2.18 0.49
IPI00382606 F7 Factor VII active site mutantimmunoconjugate 2.55 0.53
IPI00549291 IGHM IGHM protein 2.29 0.24
IPI00604537 TPM1 tropomyosin 1 α chainisoform 3 2.55 0.47
IPI00736885 LOC440786 Ig kappa chain V-IIregion TEW 3.38 0.34
IPI00743194 Kappa light chain variableregion (Fragment) 3.38 0.34
IPI00746963 IGKC IGKC protein 2.03 0.43
IPI00815926 IGHG1 IGHG1 protein 2.16 0.47
IPI00843757 TPM2 Uncharacterized proteinTPM2 (Fragment) 1.96 0.19
IPI00876888 IGHV4-31 immunoglobulin heavyvariable 4-31- cDNA FLJ78387 2.37 0.20
2.3. Immunohistochemistry
The validation of protein expression from the randomly selected markers: Plectin-1 (PLEC1),
Transketolase (TKT), HADHA Trifunctional enzyme subunit α, mitochondrial precursor and Transgelin
(TAGLN) by immunohistochemistry was successful in all cases. The proteins showed clear expression
within the tumor cells either in the nucleus or cytoplasm (Figure 1).
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Figure 1. Immunohistochemical validation of protein expression in colorectal carcinoma biopsy tissue
identified by isotope coded protein label (ICPL); (A) Plectin-1; (B) Transketolase; (C) Transgelin;
(D) HADHA Trifunctional enzyme subunit α, mitochondrial precursor.
3. Discussion
We identified a panel of predictive markers for nCRT response in rectal carcinomas with ICPL.
ICPL was recently described as powerful tool to identify thousands of proteins in extracts of body
fluids or tissue. The technique is characterized by a highly accurate and reproducible quantification
method for proteins [10,11]. ICPL is especially useful to identify regulated proteins in different samples.
It is an innovative technology, which showed its value for marker screening in human tissue samples
in our study. It was possible to validate randomly selected proteins by immunohistochemistry of
tumor biopsies. This is a further indicator for the reliability of the identified proteins. One crucial
point is the amount of tissue needed for proteome analysis. We harvested one tumor biopsy for
proteomics which is generally also needed for histological diagnosis under clinical routine conditions.
No patient suffered from any complication during sample harvesting. From our biopsies sufficient
material was accumulated after LCM to perform ICPL. Thus ICPL not only provides reliable results
but is also a valuable tool for proteome studies of human specimens which are harvested under clinical
routine conditions.
The patients who underwent nCRT were all included in a clinical trial (CAO/ARO/AIO-04) [12].
This is important because not only standardized tissue sampling and preparation but also standardized
patient care and treatment increases the value of molecular predictive marker evaluation. In our cohort
two different types of chemotherapy were added to radiation. It is not surprising that several proteins
were regulated only in relation to nCRT I or II. These markers may reflect the response to the different
chemotherapy regiments. However 14 markers were uniformly regulated in response to radiation.
Chemotherapy regiments added to nCRT change more frequently than radiation itself. Therefore these
proteins and especially the very highly expressed ones, which indicate good radiation response, may
be the most valuable for further validation in the future, because a highly expressed marker such as a
stable protein can easily be identified e.g., by immunohistochemistry in a routinely sampled tumor
biopsy under clinical conditions. PKM2, which was one of these markers, was recently described
as highly expressed in colorectal cancer and correlated with later stage, lymph node metastases and
oxaliplatin metabolism [13,14]. It is a cytosolic enzyme involved in nucleic acid, phospholipid- and
amino acid synthesis, which provides critical cell building materials for highly proliferating cells, such
as tumor cells. A high expression of Transketolase was already described in colorectal and urothelial
Int. J. Mol. Sci. 2016, 17, 209 10 of 16
cancer and was associated with poor prognosis. In breast cancer Transketolase was identified as a
potential target against tumor growth [15]. It is involved in the non-oxidative part of the pentose
phosphate pathway which is important during cell metabolism. A decrease in Transketolase expression
levels in tumor cells was assumed to delay tumor growth. These findings are indicators that several of
the markers identified in this study are related to cancer.
We classified our patients for good and poor nCRT response referring to the regression grading
of Dworak [7,16]. This histological method is based on the stroma/tumor cell relation within the
tumor after nCRT. It is a commonly used method to quantify tumor response after neoadjuvant
treatment under clinical routine. Unfortunately it is of no value for identification of response to CRT
prior to CRT application. Chemoradiation in rectal carcinoma is clinical routine as it is of clinical
benefit in certain tumors stages: It is recommended in a neoadjuvant setting prior to surgery in stage
UICC II and III rectal carcinomas. It decreases local recurrence rates and may increase anal sphincter
preservation [1,2,4,6]. Its effect on survival, especially after good or complete response to nCRT,
is currently unclear [1,2,4,6]. However, good or complete response to nCRT is seen in only about
60% of patients [9]. The rest of the patients show moderate or poor response to CRT. In these cases
nCRT does not add any benefit to the patients, but increases perioperative risks and postoperative
morbidity. Furthermore these patients are unnecessarily exposed to partially severe side effects of
CRT [1]. Molecular markers may help to identify responders to nCRT. Tools such as these are urgently
needed to predict the risk/benefit ratio for the patients during clinical routine.
4. Material and Methods
4.1. Patients and Tumor Biopsies
The study was carried out after obtaining ethical approval by the ethical commission University
of Erlangen (ID 3784). For the ICPL analysis, 20 patients with histopathology-proven rectal
adenocarcinoma (stage UICC II–IV)—which were recruited for a standardized clinical study
(CAO/ARO/AIO-04)—were selected after informed consent [12]. Patients with synchronous second
colon carcinomas or younger than 18 years of age were excluded. Tumors with a distance of maximal
16 cm from the anal verge (measured by a rigid endoscopy) were classified as rectal carcinomas.
Patients received a total dose of 50.4 Gy radiation, fractioned in 28 ˆ 1.8 Gy single applications.
During radiation they received either 5-Fluorouracil (5-FU: 1000 mg/m2/day; nCRT I) or 5-FU
(250 mg/m2/day + Oxaliplatin 50 mg/m2/day; nCRT II) [12]. Patient characteristics are listed
in Table 2.
Table 2. Patients and histopathological tumor characteristics of rectal adenocarcinomas which
underwent laser capture microdissection and proteome analysis by isotope coded protein label (ICPL);
nCRT I: 50.4 Gy + 5-FU; nCRT II: 50.4 Gy + 5-FU/Oxaliplatin.
Patients nCRT I nCRT II
n 10 10
Male 9 7
Female 2 3
ypT-category
yT0 1 3
yT1 0 0
yT2 3 1
yT3 5 6
yT4 1 0
ypN-category
yN0 4 7
yN1 5 3
yN2 1 0
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Table 2. Cont.
Patients nCRT I nCRT II
Distant metastasis
M0 9 9
M1 1 1
Grading
G1/2 6 6
G3/4 3 2
GX 1 2
Regression Grading (Dworak)
Dworak 1 2 0
Dworak 2 3 5
Dworak 3 4 2
Dworak 4 1 3
Tumor biopsies of all patients were performed prior to nCRT by rigid rectoscopy. The samples
used for ICPL were immediately harvested in liquid nitrogen and stored by ´80 ˝C until further
processing. Samples used for immunohistochemistry examination underwent a formalin fixation and
paraffin embedding procedure (FFPE). Standardized surgery such as total mesorectal excision (TME)
was performed in all cases.
4.2. Study Protocol
Endoscopic tumor biopsies were obtained from patients with histopathologically confirmed rectal
adenocarcinoma prior to nCRT. Six weeks after completion of nCRT, respective surgery was performed
and the tumor response to nCRT was classified according to Dworak’s histopathological regression
grading. Tumors were separated into two groups regarding the Dworak’s regression grading: Dworak
1 + 2: (poor response), Dworak 3 + 4 (good response) [7,16]. Differences in the tumors’ protein
expression were identified by ICPL in the biopsies obtained prior to nCRT, comparing poor (n = 10) vs.
good (n = 10) responders (Figure 2).
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nCRT I: 50.4 Gy + 5-FU; nCRT II: 50.4 Gy + 5-FU/Oxaliplatin; tumor c lls were isolated by laser
capture microdissection (LCM) from the biopsies and proteomic analysis were performed by isotope
coded protein label (ICPL). After nCRT and surgery histopathological tumor regression grading was
scored (Dworak) and protein marker expression of the tumor biopsies was correlated with specimens’
response to nCRT.
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4.3. Laser Capture Microdissection (LCM)
For proteome analysis with ICPL tumor cells were isolated from the biopsies using laser capture
microdissection (LCM), according to published protocol [17] (Figure 3). In brief, frozen tissue of
each patient was imbedded in OCT tissue freezing medium, cut into 8–10 µm thick sections using
Leica Cryostat Jung CM 3000 (Leica Microsystems Vertrieb GmbH, Wetzlar, Germany) at ´20 ˝C, and
mounted onto a PET-membrane with 1.0 mm thickness (Carl Zeiss MicroImaging GmbH, Göttingen,
Germany). The sectioned tissues were stored for further preparation at ´25 ˝C. For tissue staining, the
cresyl violet protocol, Carl Zeiss (Carl Zeiss MicroImaging GmbH, Göttingen, Germany) with minor
modification was used. In brief, the sectioned tissues were dried with cold 70% ethanol for 2 min,
stained for 30 s in cresyl violet solution containing 1% (w/v) cresyl violet acetate and 50% ethanol,
and rinsed with 70% ethanol followed by 100% ethanol. The stained tissues were air-dried for 2 min
and LCM was then performed using PALM MicroBeam MB IV (Carl Zeiss MicroImaging GmbH,
Göttingen, Germany) with approximately 100 mm2 total area cut per tissue sample, which corresponds
to a protein amount of at least 20 µg. Proteins were solubilized out of microdissected tissue for
30 min with 30 µL guanidine/HEPES pH 8.5, centrifuged at 10,000ˆ g at 4 ˝C for 15 min and sonicated
5 times for 10 s. The protein samples were pooled, due to material limitations of biopsies. The pooling
was performed in accordance with the histopathological response grading of the specimens to nCRT
(Dworak 1 + 2 or Dworak 3 + 4) [7].
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4.4. Isotope Coded Protein Labeling (ICPL)
Before ICPL-labeling, acetone precipitation of solubilized and pooled proteins from microdissected
(LCM) tissue was performed [10,11]. To one volume of each sample 5 volumes of 100% acetone cooled
to ´20 ˝C were added and incubated overnight at ´20 ˝C. Precipitated proteins were pelleted by
centrifugation 30 min at 20,000ˆ g at 4 ˝C. Pellets were washed twice with cold 80% (v/v) acetone by
centrifugation for 5 min at 20,000ˆ g at 4 ˝C. The protein concentration was determined by a Bradford
assay (BioRad Laboratories GmbH, Munich, Germany) before and after acetone precipitation, the last
of which was used to adjust sample concentration at 5 µg/µL in ICPL-lysis buffer (40 µL) containing
6 M guanidine-HCL and 0.1 M HEPES pH 8.5. For ICPL-labeling, cysteines were reduced by adding of
1 µL of 2 M TCEP in 0.1 M HEPES pH 8.5 into each of the 4 samples and overfilled with argon. After
vortexing for 30 s and 1 min ultrasonic treatment, the samples were incubated for 30 min at 60 ˝C.
For alkylation of cysteines 1 µL of 0.4 M IAA (Iodoacetamide) in 0.1 M HEPES pH8.5 was added into
each of the 4 samples and incubated for 30 min at 25 ˝C. Alkylation was quenched by adding 0.5 M
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N-acetyl cysteine solution in 0.1 M HEPES pH 8.5 followed by incubation for 15 min at 25 ˝C. For the
differential labeling, four ICPL-reagents, ICPL0, ICPL4, ICPL6 and ICPL10, were used as a quadruplex
approach. Proteins were then labeled with one of the 4 ICPL reagents (6 µL of 0.15 M ICPL0, ICPL4,
ICPL6 or ICPL10). The reaction was allowed to proceed for 2 h at 25 ˝C under a nitrogen atmosphere to
minimize methionine oxidation. Labeling was quenched by addition of hydroxylamine (1.5 M, pH 8.3),
and all four samples were combined and stored by ´20 ˝C. From each of the two separately prepared
technical replicates, the sample amount was divided for the OFFGEL-fractionation (95%; 150 µg) and
for non-fractionation (5%; 10 µg). For OFFGEL-fractionation , ICPL-labeled and combined proteins
(150 µg) were fractionated by isoelectric point (pI) using an Agilent 3100 OFFGEL fractionator (Agilent
Technologies, Oberhaching, Germany) according to the manufacturer’s instructions The samples from
the first technical replicate (24 OFFGEL-fractions and non-fractionated sample) were analyzed after
in-solution digestion with the enzymes Glu-C und Trypsin [17] by the Core Facility (Max-Planck
Institute for Biochemistry, Martinsried, Germany) with the LTQ-hybrid mass spectrometer (Thermo
Fischer Scientific, Bremen, Germany). Nano-LC-MS/MS was performed on an LTQ-Orbitrap mass
spectrometer (Thermo Fisher Scientific, Schwerte) coupled to a nanoHPLC Agilent 1200 system (Agilent
Technologies Deutschland GmbH, Böblingen, Germany). Briefly, peptides were preconcentrated
on a reversed-phase (RP) trapping column (15 cm-fused silica column with 75 µm ID filled with
ReproSil-Pur C18-AQ 3 µm resin (Dr. Maisch GmbH, Ammerbuch-Entringen, Germany) in 0.1% TFA
(Trifluoroacetic) using a gradient from 2% to 40% in 0.5% acetic acid in ACN (Acetonitrile) at a flow
rate of 250 nL/mL in 100 min.
MS (Mass Spectrometry) survey scans were acquired within the Orbitrap from 300 to 1800 m/z at
a resolution of 60.000. The ten most intense signals were subjected to collision induced dissociation
(CID) in the ion trap. The samples from the second technical replicates (24 OFFGEL-fractions and
non-fractionated sample) were also analyzed after in-solution digestion with the enzymes Glu-C und
Trypsin [18] by the group of A. Sickmann (Leibniz–Institut für Analytische Wissenschaften-ISAS-e.V.,
Dortmund, Germany) with the LTQ-Orbitrap Velos (Thermo Fisher Scientific, Bremen, Germany).
Nano-LC-MS/MS was performed on an LTQ-Orbitrap Velos mass spectrometer (Thermo Fisher
Scientific, Bremen, Germany) coupled to an Ultimate 3000 Rapid Separation Liquid Chromatography
(RSLC) system (Dionex, Germering, Germany). Briefly, peptides were preconcentrated on a
reversed-phase (RP) trapping column (Acclaim PepMap, 75 µm ˆ 2 cm C18, 100 Å, Dionex) in
0.1% TFA followed by RP separation (Acclaim PepMap RSLC 75 µm ˆ 15 cm, 2 µm, 100 Å, Dionex)
using a binary gradient (solvent A: 0.1% FA, solvent B: 0.1% FA, 84% ACN) from 5% to 50% B at a flow
rate of 300 nL/min in 90 min.
MS survey scans were acquired within the Orbitrap from 300 to 2000 m/z at a resolution of
60,000 using polysiloxane m/z 445.120030 as lock mass. The ten most intense signals were subjected to
collision induced dissociation (CID) in the ion trap taking into account a dynamic exclusion of 12 s.
CID spectra were acquired with a normalized CE (collision energy) of 35%, a default charge state of
2 and an activation time of 30 ms. AGC target values were set to 104 for ion trap MSn and 106 for
Orbitrap MS scans.
Since only ICP-samples have been analyzed, these generated MS/MS spectra or MSn
spectra were evaluated by the ICPL-ESIQuant software (Max-Planck Institut for Biochemistry,
Martinsried, Germany).
4.5. Immunohistochemistry
Selection of markers for immunohistochemistry was performed randomly. Four proteins have
been selected for immunohistochemical validation in rectal carcinoma biopsies which were sampled
prior to nCRT and fixed in formalin and paraffin embedded. Tissue sections (4 µm) were dewaxed in
xylene and rehydrated. For staining, antigene retrieval was performed for 20 min at 95 ˝C in citrate
target retrieval solution pH 6.0 (DAKO, Hamburg, Germany) or tissue sections were digested with
hyaluronidase from bovine testis (2 mg/mL in PBS, pH 5.5, Sigma Aldrich, Taufkirchen, Germany)
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and protease from Streptomyces griseus (1 mg/mL in PBS, pH 7.4, Sigma Aldrich) for 30 min each at
37 ˝C. Sections were incubated with antibodies raised against human anti-HADHA (ab54477, Abcam,
Cambridge, UK), anti-SM22 α [1B8] (Transgelin) (ab28811, Abcam, Cambridge, UK), anti-Transketolase
[7H1AA1] (ab112997, Abcam, Cambridge, UK) and anti-Plectin [E398P]; (ab32528, Abcam, Cambridge,
UK). As a control, sections were incubated with the same concentration of non binding isotypic
mouse immunoglobulins. Immunostaining was detected using the ZytoChem-Plus AP (Alkaline
phosphatase) polymer kit (Zytomed Systems, Berlin, Germany) and liquid permanent red (DAKO)
according to the manufacturers’ instruction. Slides were counterstained with gill-3 haematoxylin
(Merck, Darmstadt, Germany), air-dried and mounted with VectaMount permanent mounting medium
(Vector Laboratories, Burlingame, CA, USA) (Figure 1).
4.6. Statistics
Identification and quantification of the proteins were examined separately for the nCRT I
and nCRT II group. Before quantification, the raw files were de-isotoped and deconvoluted by
the extract function of the Trans Proteomic Pipeline software (TPP); Version 4.3 (Seattle Proteome
Center, Washington, WA, USA) and transformed to an mzXML data format. Then quantification
was performed using the ICPL-ESIQuant version 2.0 software [19]. Selected parameters were
chosen as follows: mass accuracy 60 ppm, co-elution count: ě2 and ICPL (label 0, monoisotopic
mass = 105.02), ICPL:2H(4) (label 4, monoisotopic mass = 109.04), ICPL:13C(6) (label 6, monoisotopic
mass = 111.04), and ICPL:13C(6)–2H(4) (label 10, monoisotopic mass = 115.06). For identification,
proteins were searched against the IPI (International Protein Index) database using of MASCOT, Version
2.2 (Matrix Science, London, UK) with the following parameter settings: Homo sapiens as organism,
carbamidomethylation (C) as a fixed modification, variable modification of oxidized methionine, all
4 variable Protein Nterm and ICPL(K) labels, trypsin digestion with one missed cleavage allowed,
minimum Mascot protein score ě60.0 and minimum Mascot peptide score ě20.0. For the reliability of
the reported database search results an automatic decoy database search was performed with the same
selected parameters as described above.
4.7. Quantification and Identification of Potential Protein Signatures
The ICPL-ESIQuant software (Max-Planck Institut for Biochemistry, Martinsried, Germany)
was used for the evaluation of the total 50 individual samples (2 ˆ 24 OFFGEL-fractions and 2ˆ
non-fractionated samples). Proteins are considered to be quantified and identified, if at least two
multiplets per protein and a unique peptide per protein were available. In case of a protein that was
identified in neighboring OFFGEL-fractions, this protein was regarded as a single protein species. In
case of a protein identified in several OFFGEL-fractions, but not in between two fractions, this protein
was regarded as a separate protein species or isoform.
The identified proteins were classified as differentially expressed with a regulation value of
1.5 ě 1 ě 0.66, with at least two quadruplets per protein and a unique peptide per protein (CV ď 30%).
5. Conclusions
In summary we identified a panel of proteome markers which may act as response predictors
for neoadjuvant CRT in rectal carcinomas in the future. The main limitation of our study is a limited
patient cohort from which we derived our data. For this reason our results have to be considered
as preliminary. In a next step these markers must be validated in an independent patient cohort
prospectively to elucidate its value for clinical use.
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